$PVCT second news email today! Provectus News
Post# of 22711
Provectus News
Overview of Intralesional Therapy for Melanoma: Focus on PV-10
Tuesday October 14, 2014
Dr. Sanjiv Agarwala of St. Luke's Cancer Center recently presented data on investigational new drug PV-10 for the treatment of melanoma at the III Eurasian Melanoma and Skin Cancers Forum, in Suzdal, Russia. Slides from Dr. Agarwala's presentation are now available on the Provectus website at:
www.pvct.com/presentation/2014+Suzdal+IL+Therapy+Focus+on+PV-10.pdf/
PV-10 well-tolerated in treatment of refractory cutaneous melanoma
Tuesday October 14, 2014
An article appearing in the Dermatology News section of Healio reports on the poster presented at the European Society of Medical Oncology Annual Congress (ESMO), showing that intralesional injection of PV-10 was well-tolerated in patients with refractory cutaneous melanoma, with just over half of patients meeting the primary study endpoint. The article is available from the Healio website at the following link.
PV-10 well-tolerated in treatment of refractory cutaneous melanoma
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
![937206596_images.jpg](https://investorshangout.com/images/MYImages/937206596_images.jpg)